About the Event
When Avior Bio’s founder, President, and CEO, Niraj Vasisht, PhD saw his uncle suffering from pruritis brought on by liver disease, he knew he had to do something. There are no effective treatments for the persistent and intractable itching that approximately 20 million Americans suffer from.
Often described as like having bugs crawling under your skin 24 hours a day, pruritus is a debilitating condition that causes worsening quality-of-life, sleep disturbance, depression, severe excoriation, bleeding, and increased mortality risks. Avior is well on its way to developing the first and only once-daily oral transmucosal film treatment for pruritis.
Join our webinar to hear from Mr. Vasisht, and how Avior is ready to enter Phase 2 Clinical Trials for its treatment for pruritis, a $1.3 billion market opportunity with a clear unmet need.